{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:53:41Z","timestamp":1785020021666,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01500-3","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:32:50Z","timestamp":1779769970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Surgical Intervention After Zolbetuximab-Based Chemotherapy for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A Case Series"],"prefix":"10.1007","volume":"57","author":[{"given":"Shutaro","family":"Oiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"23","key":"1500_CR1","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"issue":"10389","key":"1500_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 as first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (SPOTLIGHT): a multicenter, randomized, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"1500_CR3","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX as first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (GLOW): a multicenter, randomized, double-blind, phase 3 trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"12","key":"1500_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med. 2024;391(12):1159\u201362. https:\/\/doi.org\/10.1056\/NEJMc2409512.","journal-title":"N Engl J Med"},{"issue":"2","key":"1500_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Yasufuku I, Terashima M, Rha SY, Bae JM, Li G, CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO), et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2021;6(2):227\u201340. https:\/\/doi.org\/10.1002\/ags3.12515.","journal-title":"Ann Gastroenterol Surg"},{"issue":"3","key":"1500_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomized controlled trial. Lancet Oncol. 2016;17(3):309\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(15)00553-7.","journal-title":"Lancet Oncol"},{"key":"1500_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-025-00804-8","author":"Y Ushimaru","year":"2025","unstructured":"Ushimaru Y, Yamamoto K, Yanagimoto Y, Masuike Y, Yamamoto K, Matsuura N, et al. Conversion surgery following zolbetuximab-based chemotherapy for CLDN18.2-positive gastroesophageal junction cancer. Int Cancer Conf J. 2025. https:\/\/doi.org\/10.1007\/s13691-025-00804-8.","journal-title":"Int Cancer Conf J"},{"issue":"2","key":"1500_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.21873\/invivo.13900","volume":"39","author":"E Yakuwa","year":"2025","unstructured":"Yakuwa E, Shoji Y, Oizumi T, Kobayashi Y, Motoishi T, Katagiri T, Suzuki S. Safety and feasibility of outpatient zolbetuximab administration in community cancer care: a mixed-methods analysis. Vivo. 2025;39(2):951\u201360. https:\/\/doi.org\/10.21873\/invivo.13900.","journal-title":"Vivo"},{"key":"1500_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.70352\/scrj.cr.25-0536","volume":"12","author":"S Shirao","year":"2026","unstructured":"Shirao S, Arigami T, Matsushita D, Shimonosono M, Okubo K, Noda M, et al. Successful conversion surgery after zolbetuximab-based chemotherapy for Claudin 18.2-positive gastric cancer with peritoneal dissemination and cervical lymph node metastasis: a case report. Surg Case Rep. 2026;12:25\u20130536. https:\/\/doi.org\/10.70352\/scrj.cr.25-0536.","journal-title":"Surg Case Rep"},{"issue":"4","key":"1500_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/reports8040235","volume":"8","author":"S Oyama","year":"2025","unstructured":"Oyama S, Suzuki S, Kabasawa T, Kanauchi T, Akiba S. A mucosal change like hypertrophic gastritis following zolbetuximab-based therapy in a conversion surgery case of advanced gastric cancer. Reports. 2025;8(4):235. https:\/\/doi.org\/10.3390\/reports8040235.","journal-title":"Reports"},{"issue":"2","key":"1500_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: proposal of new biological categories. Gastric Cancer. 2016;19(2):329\u201338. https:\/\/doi.org\/10.1007\/s10120-015-0575-z.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1500_CR12","doi-asserted-by":"publisher","first-page":"1967080","DOI":"10.1080\/21688370.2021.1967080","volume":"10","author":"D Kyuno","year":"2022","unstructured":"Kyuno D, Takasawa A, Takasawa K, Ono Y, Aoyama T, Magara K, et al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022;10(1):1967080. https:\/\/doi.org\/10.1080\/21688370.2021.1967080.","journal-title":"Tissue Barriers"},{"issue":"5","key":"1500_CR13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27(5):1058\u201368. https:\/\/doi.org\/10.1007\/s10120-024-01518-1.","journal-title":"Gastric Cancer"},{"issue":"9","key":"1500_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, T\u00fcreci \u00d6. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49(9):870\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyz068.","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"1500_CR15","doi-asserted-by":"publisher","first-page":"105805","DOI":"10.1016\/j.esmoop.2025.105805","volume":"10","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, Owaki Y, Nakayama I, Sakamoto N, Ishizaka M, Kadota T, et al. Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. ESMO Open. 2025;10(10):105805. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105805.","journal-title":"ESMO Open"},{"issue":"7517","key":"1500_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"issue":"6","key":"1500_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s10120-022-01324-7","volume":"25","author":"W Wang","year":"2022","unstructured":"Wang W, Ye LF, Bao H, Hu MT, Han M, Tang HM, et al. Heterogeneity and evolution of tumor immune microenvironment in metastatic gastroesophageal adenocarcinoma. Gastric Cancer. 2022;25(6):1017\u201330. https:\/\/doi.org\/10.1007\/s10120-022-01324-7.","journal-title":"Gastric Cancer"},{"issue":"5","key":"1500_CR18","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/cas.14191","volume":"110","author":"SWT Ho","year":"2019","unstructured":"Ho SWT, Tan P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Sci. 2019;110(5):1520\u20139. https:\/\/doi.org\/10.1111\/cas.14191.","journal-title":"Cancer Sci"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01500-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:33:11Z","timestamp":1779769991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01500-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01500-3","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study protocol was reviewed and approved by the institutional review board of Hokkaido Cancer Center (approval number: No. 07\u201311).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Due to the retrospective nature of this case series, the requirement for written informed consent was waived by the institutional review board, and an opt-out consent procedure was implemented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors affirm that informed consent for publication of all images included in this article was obtained from the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}